23 June 2025 - Breakthrough therapy designation based on promising early clinical evidence observed with daraxonrasib in patients with pancreatic ductal adenocarcinoma.
Revolution Medicines today announced that the US FDA has granted breakthrough therapy designation to daraxonrasib, the company’s RAS multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma in patients with KRAS G12 mutations.